Trial · NCT01247571
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Tumor Response (Complete or Partial) | Pazopanib | 0 | 90% Confidence Interval 0 to 14.6 | percentage of participants | |
| Percentage of Participants With Progression-free Survival (PFS) at 6 Months | Pazopanib | 15.8 | 90% Confidence Interval 4.4 to 35.9 | percentage of participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Anemia | 3 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Hypertension | 3 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Abdominal pain | 2 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Hyperglycemia | 2 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Hypoglycemia | 2 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Alanine aminotransferase increased | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Ascites | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Aspartate aminotransferase increased | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Creatinine increasead | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Death NOS | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Dehydration | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Diarrhea | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Dyspnea | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Fatigue | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Headache | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Hypocalcemia | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Hyponatremia | 1 | participants | |
| Number of Patients With Grade 3 or Higher Adverse Events | Pazopanib | Memory impairment | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01247571/results